Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis.
Pei-Yu ChenLingfeng QinGuangxin LiZheng WangJames E DahlmanJose Malagon-LopezSharvari GujjaNicholas A CilfoneKevin J KauffmanLele SunHongye SunXinbo ZhangBinod AryalAlberto Canfran-DuqueRebecca LiuPascal KustersAlfica SehgalYang JiaoDaniel G AndersonJeffrey GulcherCarlos Fernández-HernandoEsther LutgensMartin A SchwartzJordan S PoberThomas W ChittendenGeorge TellidesMichael SimonsPublished in: Nature metabolism (2019)
Atherosclerosis is a progressive vascular disease triggered by interplay between abnormal shear stress and endothelial lipid retention. A combination of these and, potentially, other factors leads to a chronic inflammatory response in the vessel wall, which is thought to be responsible for disease progression characterized by a buildup of atherosclerotic plaques. Yet molecular events responsible for maintenance of plaque inflammation and plaque growth have not been fully defined. Here we show that endothelial TGFβ signaling is one of the primary drivers of atherosclerosis-associated vascular inflammation. Inhibition of endothelial TGFβ signaling in hyperlipidemic mice reduces vessel wall inflammation and vascular permeability and leads to arrest of disease progression and regression of established lesions. These pro-inflammatory effects of endothelial TGFβ signaling are in stark contrast with its effects in other cell types and identify it as an important driver of atherosclerotic plaque growth and show the potential of cell-type specific therapeutic intervention aimed at control of this disease.
Keyphrases
- endothelial cells
- oxidative stress
- transforming growth factor
- inflammatory response
- cardiovascular disease
- coronary artery disease
- randomized controlled trial
- multiple sclerosis
- single cell
- magnetic resonance
- stem cells
- bone marrow
- metabolic syndrome
- magnetic resonance imaging
- risk assessment
- lipopolysaccharide induced
- contrast enhanced
- toll like receptor